Cytovation

Next generation immunotherapy for cancer treatment

Cytovation4

Founded: 2014

HQ: Bergen, Norway

Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell membrane of tumor cells. 

The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. 

In 2021 Cytovation entered into a clinical trial collaboration and supply agreement with MSD to evaluate the safety and efficacy of CyPep-1 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy. The Phase II trial is scheduled to start early 2022.

Other companies we believe in

CMR SurgicalHigh precision surgery through robotics

Salient EnergyPowering the clean energy revolution with zinc-ion batteries

Delft IMPEnhancing battery life through nanotechnology

Hallgruppen Hallgruppen Flexible storage halls and relocatable structures

Antec BiogasAccelerating biogas production

Standard BioTurning biowaste into valuable products

PickataleMaking reading for children fun and easy

DolphitechNext generation ultrasonic platform for non-destructive testing

XerisMaking product information more accessible

Turbulent FluxMonitor your production to reduce well testing frequency

Wrepit Enabling anyone to create inspiring, accessible, written content

Subscribe

Stay in the loop - sign up for our newsletter

Sandwater
Universitetsgata 12
Oslo, Norway

hello(at)sandwater.com